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1. Introduction
Dengue viruses (DV) belong to family Flaviviridae and 
have four serotypes (1 to 4). They are transmitted mainly by 
the Aedes aegypti mosquito and also by Aedes albopictus. 
Biologically, DV are highly adapted to the mosquito and 
are maintained by vertical transmission. DV produces from 
a subclinical infection to a mild self limiting disease, the 
dengue fever (DF) and a severe disease that may be fatal, 
the dengue haemorrhagic fever/ dengue shock syndrome 
(DHF/DSS). The mosquito vectors are present in tropical 
and subtropical regions of the earth that determines the 
prevalence of DV in a region. Prior to 1970, only 9 countries 
had experienced cases of DHF; since then the number has 
increased more than 4-fold and continues to rise (fi gure 1a). 
The WHO published a global map of the distribution of the 
dengue epidemic activity during the year 2006 that shows 
whole India in red colour (fi gure 1b). A comparison with 
similar maps prepared in earlier years shows that the activity 
of both the vector and the virus has spread to newer areas, 
acquiring global public health importance. An estimated 
2.5 billion people in more than 100 countries are at risk of 
acquiring dengue viral infection with more than 50 million 
new infections being projected annually, 500000 cases of 
DHF that must be hospitalized and 20000–25000 deaths, 
mainly in children (Halstead 2002, 2007; Chaturvedi and 
Shrivastava 2004). Dengue has been an urban disease but 
now has spread to rural areas of India as well (Mehendale et 
al 1991; Kumar et al 2001; Arunachalam et al 2004; Tewari 
et al 2004). The factors considered responsible for Global 
resurgence of DF/DHF are unprecedented population growth, 
unplanned and uncontrolled urbanization, increased Air 
travel, absence of an effective mosquito control programme 
and deterioration of Public Health infrastructure. The risk 
factors for infection with DV are the increased density of 
the mosquito vector, reinfestation with Ae. aegypti of a 
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new geographical area, warm and humid climate, increased 
population density, water storage pattern in houses, storage 
of junk in open spaces, including tyres, coconut shells etc 
that trap rain water and introduction of new serotype of the 
virus, etc. Vaccines or antiviral drugs are not available for 
dengue viruses; the only effective way to prevent epidemic 
DF/DHF is to control the mosquito vector, Ae. aegypti and 
prevent its bite.
2. Dengue virus and immune response
DV is a positive-stranded encapsulated RNA virus and is 
composed of three structural protein genes, which encode 
the nucleocapsid or core (C) protein, a membrane-associated 
(M) protein, an enveloped (E) glycoprotein and seven non-
structural (NS) proteins. Anti-E antibodies neutralize DV 
infectivity in vitro and protect mice from DV challenge on 
passive transfer and show a variable degree of cross-reactivity 
among the DV serotypes. Antibodies against NS1 can trigger 
complement-mediated lysis of DV-infected cells in vitro and 
protect mice from DV challenge. At the same time these 
antibodies may cross-react with endothelial cells leading to 
their activation and expression of cytokine, chemokine, and 
adhesion molecules resulting in cell damage. NS3 protein is 
the main antigen that stimulates DV-reactive CD4+ and CD8+ 
T cells that produce high levels of IFN-γ as well as TNF-α, 
TNF-β, and chemokines including macrophage inhibitory 
protein-1β upon interaction with DV-infected antigen 
presenting cells, and are effi cient at lysis of DV-infected cells 
in vitro (reviewed by Chaturvedi et al 2006a). 
3. Clinical presentation
The patients initially develop an abrupt onset of high 
fever (39–40°C) with headache, retro-orbital pain, malaise, 
nausea, vomiting, and myalgia. The acute febrile stage lasts 
2–7 days and may be followed by recovery but patients feel 
weakness. During defervescence some patients develop 
haemorrhagic manifestation that may be mild petechial 
haemorrhage, and bleeding at the nose, gastrointestinal tract 
and gums, which may be severe. Menorrhagia has been 
more prevalent due to the increasing number of affected 
adolescents, but haematuria is rare. Hepatomegaly is common 
with soft and tender liver. Thrombocytopoenia and rising 
haematocrit due to plasma leakage are usually detectable 
before the onset of the subsequent stage of shock (DSS) with 
an abrupt fall to normal or subnormal levels of temperature, 
varying degrees of circulatory disturbances lasting for 24–48 
h. In recent publications a number of atypical manifestations 
of dengue, such as encephalitis/encephalopathy (Kumar
et al 2008) and myocarditis, hepatitis and cholecystitis etc. 
have been reported (Gulati and Maheshwari 2007). The 
majority of patients have rapid uneventful recovery without 
sequelae in the convalescent stage. The sequence of events 
in a patient after bite of infected mosquito is summarized 
in fi gure 2. The clinical diagnosis of DHF is based on 
four main characteristic manifestations (WHO 1997): (i) 
continuous high fever lasting 2–7 days; (ii) haemorrhagic 
tendency as shown by a positive tourniquet test, petechiae or 
epistaxis; (iii) thrombocytopoenia (platelet count less than 
100 × 109/l); and (iv) evidence of plasma leakage manifested 
by hemoconcentration (an increase in haematocrit 20% 
Figure 1. Global prevalence of dengue fever (DF) and dengue haemorrhagic fever (DHF) as shown by the WHO. (a) Average number of 
cases and the number of countries affected since 1955. (b) World map showing the prevalence of dengue virus before 1960 and during the 
year 2006. http://www.who.int/csr/disease/dengue/impact/ en/index.html. Reproduced with permission of  the WHO.
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above average for age, sex and population), pleural effusion 
and ascites etc. But some patients with bleeding or anemia 
may not have a rising haematocrit. Therefore, close 
observation, serial haematocrit and daily platelet count 
monitoring are suggested to fulfi ll the clinical diagnostic 
criteria. The severity of DHF is categorized into four 
grades (WHO 1997): grade I, being the mildest and 
grade IV being most severe, with circulatory failure 
manifested by a rapid and weak pulse with narrowing 
of pulse pressure (20 mmHg) or hypotension, with the 
presence of cold clammy skin and restlessness. There may 
be profound shock in which pulse and blood pressure are 
not detectable (DSS). In such patients the mortality rate is 
high. 
4. Principles of laboratory diagnosis
Diagnosis of dengue virus infection is confi rmed in the 
laboratory. During the stage of fever there is viraemia 
(fi gure 2) with presence of NS1 antigens in blood. The 
presence of virus in blood is detected either by isolation 
of the virus using infant mice or in tissue culture or by RT-
PCR and the NS1 is detected by ELISA. During the post-
febrile stage lasting a few weeks, IgM and IgG antibodies 
are present and are detected by Capture- ELISA (fi gure 2). 
During primary infection, viraemia and fever coincides, 
but during a secondary infection (second time infection 
with DV), the viraemia is present for 2 to 3 days, and NS1 
antigens in blood lasts little longer. With a newer approach, 
artifi cial NS1 receptors have been implanted on a reuseable 
microchip that can capture and identify NS1 instantly and 
may be used for bedside diagnosis of dengue virus infection 
(Tai et al 2006). 
5. Work done in India 
This review is biased towards the work done in this country, 
reporting new virological/ pathological fi ndings, efforts for 
the development of a vaccine or a diagnostic kit and are 
refl ected in PubMed. Even then all the papers could not be 
cited due to constraint of space.
5.1 History of dengue
Dengue fever is an ancient disease. A clinical dengue-like 
illness was recorded in a Chinese medical encyclopedia 
in 992. With the expansion of shipping and growth of port 
cities in the 18th and 19th centuries the mosquito vector, Ae. 
aegypti and the dengue viruses spread to new geographic 
areas causing major epidemics. After the World War II, rapid 
urbanization in Southeast Asia led to increased transmission 
and hyperendemicity. The fi rst epidemic of clinical dengue-like 
illness was recorded in Madras in 1780. Table 1 summarizes 
the occurrence of the epidemics of dengue-like illness in India. 
(Gubler 1997). Dengue virus was isolated in Japan in 1943 by 
inoculation of serum of patients in suckling mice (Kimura and 
Hotta 1944). The virus was isolated from sera of US soldiers 
at many parts of the World including Calcutta during 1944 
(Sabin and Schlesinger 1945). The fi rst virologically proved 
epidemic of DF in India occurred in Calcutta (now Kolkata) 
and Eastern Coast of India in 1963–1964 (Sarkar et al 1964; 
Chatterjee et al 1965; Carey et al 1966). The fi rst major 
epidemic of the DHF occurred in 1953–1954 in Philippines 
followed by a quick global spread of epidemics of DF/DHF 
(Rigau-Perez et al 1998). DHF was occurring in the adjoining 
countries but it was absent in India for unknown reasons as all 
the risk factors were present. The DHF started simmering in 
Figure 2. Sequence of events during dengue virus infection  following the bite of infected mosquito.
various parts of India since 1988 (Kabra et al 1992; Chaturvedi 
U C, Mukerji R and Nagar R, unpublished data; Bhattacharjee 
et al 1993; Cherian et al 1994). The fi rst major wide spread 
epidemics of DHF/DSS occurred in India in 1996 involving 
areas around Delhi (Dar et al 1999) and Lucknow (Agarwal et 
al 1999a) and then it spread to all over in the country (Singh et 
al 2000; Shah et al 2004).
5.2 Virological investigation of epidemics of DF/DHF
In this vast country virus laboratories are few and wide 
apart, therefore, large section of the population has no 
facilities for viral diagnosis. Now diagnosis by commercial 
kits is available to many hospitals. After the initial epidemic 
of dengue fever on the Eastern Coast of India in 1963–64 
(Sarkar et al 1964; Chatterjee et al 1965; Carey et al 1966), 
it spread Northwards and reached Delhi in 1967 (Balaya et 
al 1969) and Kanpur in 1968 (Chaturvedi et al 1970a, b). 
Gradually the whole country was involved with wide spread 
epidemics followed by endemic/hyper-endemic prevalence 
of all the four serotypes of DV. 
The epidemiology of dengue virus and its prevalent 
serotypes has been ever changing. The epidemic at Kanpur 
during 1968 was due to DV-4 (Chaturvedi et al 1970a) and 
during 1969 epidemic; both DV-2 and DV-4 were isolated 
(Chaturvedi et al 1972). It was completely replaced by 
DV-2 during 1970 epidemic in the adjoining city of Hardoi 
(Chaturvedi et al 1974). Myers et al (1968, 1969) had 
reported the presence of DV-3 in patients and Aedes aegypti 
at Vellore during the epidemic of 1966 while during the 
epidemic of 1968, all the four types of DV were isolated 
from patients and mosquitoes (Myers et al 1970). In another 
study Myers and Varkey (1971) reported an instance of a 
third proved attack of DV in one individual. DV-2 was 
isolated during the epidemics of dengue in urban and rural 
areas of Gujrat state during 1988 and 1989 (Mahadev et al 
1993). Outbreaks of dengue occurred in Rajasthan by DV- 1 
and DV-3 (Ghosh et al 1974), DV-3 (Chauhan et al 1990), 
Madhya Pradesh by DV-3 (Rodriguez et al 1973), Jammu 
by DV-2 (Padbidri et al 1996), Gujarat by DV-2 (Mahadev 
et al 1993) and in Haryana by DV-2 (Kumar et al 2001). 
DV-2 was the predominant serotype circulating in Northern 
India, including Delhi, Lucknow and Gwalior (Dar et al 
1999; Agarwal et al 1999a; Parida et al 2002) while DV-1 
was isolated during the 1997 epidemic at Delhi (Kurukumbi 
et al 2001). The phylogenetic analysis by the Molecular 
Evolutionary Genetics Analysis program suggests that the 
1996 Delhi isolates of DV-2 were genotype IV. The 1967 
isolate was similar to a 1957 isolate of DV-2, P9-122, from 
India, and was classifi ed as genotype V. This study indicates 
that earlier DV-2 strains of genotype V have been replaced 
by genotype IV (Singh et al 1999). The Gwalior DV-2 
viruses, were classifi ed into genotype-IV, and were most 
closely related to Delhi 1996 DV-2 viruses and FJ 10/11 
strains prevalent in the Fujian state of China. However, two 
earlier Indian isolates of DV-2 were classifi ed into genotype-
V. Genotype V of DV-2 has been replaced by genotype IV 
during the past decade, which continues to circulate silently 
in North India, and have the potential to reemerge and cause 
major epidemics of DF and DHF (Dash et al 2004).
DV-3 has been isolated during the epidemics at Vellore in 
1966 (Myers et al 1968; 1969), at Calcutta in 1983 (Mukherjee 
et al 1987) and in 1990 (Bhattacharjee et al 1993), at Jalore 
city, Rajasthan in 1985 (Chouhan et al 1990) at Gwalior 
in 2003 and 2004 (Dash et al 2005, 2006). At Delhi, till 
2003, the predominant serotype was DV-2 (genotype IV) 
but in 2003 for the fi rst time all four dengue virus subtypes 
were found to co-circulate in Delhi thus changing it to a 
hyperendemic state (Dar et al 2003) followed by complete 
predominance of DV serotype 3 in 2005 (Gupta et al 2006). 
During the 2004 epidemic of DHF/DSS in Northern India a 
sudden shift and dominance of the DV serotype-3 (subtype 
III) occurred replacing the earlier circulating serotype-
2 (subtype IV) (Dash et al 2006). Co-circulation of DV 
serotypes in Delhi in 2005 has also been reported by Saxena 
et al (2006), which may have implications for increased 
DHF/DSS. Kukreti et al (2008) have reported emergence 
of a distinct lineage of DV-1, having similarity with the 
Comoros/Singapore 1993 and Delhi 1982 strains, but quite 
different from the Delhi 2005 lineage and microevolution of 
the pre-circulating DV-3. Co-circulation of several serotypes 
of dengue viruses has resulted in concurrent infection in 
some patients with multiple serotypes of DV (Bharaj et 
al 2008). Concurrent infection by Chikungunya and DV-2 
was reported by Myers and Carey (1967) from Vellore. In a 
recent study the economic burden faced by India during the 
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Table 1. Epidemics of dengue-like illness in India (before 
discovery of the virus)
Year Places
1780 Madras
1824–1925 Rangoon to Madras
1844–1949 Kanpur, Calcutta
1852–1956 Wide spread
1870–1973 Bombay, Calcutta, Madras
1897–1999 Bombay
1901–2007 Madras
1907–1913 Calcutta, Pune, Meerut
1920–1926 Lucknow, Bombay, Calcutta
1927–1928 Coimbatore
1930–1933 Madras
1934–1936 Madras
1940–1945 Calcutta
2006 dengue epidemic was estimated and was found to be 
US$27.4 million (95% CI US$25.7–29.1 million) (Garg et 
al 2008). 
5.3 Development of mosquito cell culture 
In a landmark study, Singh and Paul (1969) reported 
development of a mosquito cell culture for the isolation 
of dengue viruses. This was the fi rst time when mosquito 
cells were used as cell culture. This was a forerunner of the 
widely used mosquito cell line C6/36.
5.4 Pathogenesis of DHF
The pathognomonic features of DHF are increased vascular 
permeability without morphological damage to the capillary 
endothelium, thrombocytopoenia, altered number and 
functions of leucocytes, altered haemostasis and liver damage. 
Extensive plasma leakage occurs suddenly in various serous 
cavities of the body including the pleura, pericardium and 
peritoneal cavities and associated haemorrhages, in patients 
with DHF grades III and IV may result in profound shock, 
the DSS. A lot of work done in the last several decades but 
the pathogenesis of DHF is not fully understood reviewed 
by (Chaturvedi et al 2006a, b, 2007). Among the several 
hypothesis proposed to explain the pathogenesis of severe 
dengue disease, three are the landmark reports. First was the 
role of enhancing antibodies (Halstead 1970); the second 
was the demonstration of a shift from Th1-response in 
mild dengue to Th2-response in severe DHF (Chaturvedi 
et al 1999a) associated with the disturbed fi ne balance of 
the cytokine cascade resulting in a ‘Cytokine Storm’ that 
causes all the pathological lesions (Chaturvedi et al 1999a; 
2000); and the third is presence of cross-reactive memory T 
cells that induce secretion of large amount of cytokines on a 
second exposure to DV (Mongkolsapaya et al 2003, 2006). 
DV-specifi c memory lymphocytes have been detected even 
20 years after a primary infection with the virus (Sierra et 
al 2002). Whatever is the mechanism, it ultimately targets 
endothelium to produce pathological lesions and the severe 
dengue disease (Basu and Chaturvedi 2008). 
A lot of work has been done experimentally and in patients 
in this country to understand the immunopathogenesis of 
DHF and the fi ndings have been validated in the subsequent 
epidemics of DHF. Our fi ndings summarized in fi gure 3 
show that during DV infection four cascades of T cells are 
induced that might singly/jointly result in vascular leakage 
and DHF. 
5.4.1 Suppressor T cell cascade: Cascade 1: For the fi rst 
time a microbe-induced suppressor T cells cascade was 
delineated in DV-infected mice (Tandon et al 1979; Shukla 
and Chaturvedi 1981, 1983; Chaturvedi 1984) and now it 
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Figure 3. Immunopathogenesis of DHF via induction of  four cascades of T cells as dissected out by U C Chaturvedi and colleagues. 
Please see the text.
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has been confi rmed in a large number of viruses (Mills 
2004). The conclusions drawn at that time using primitive 
techniques (Chaturvedi 1984) are valid even today using 
modern technique (Mills 2004). The antigen –specifi c 
suppressor T cell cascade in DV-infected mice consists 
of three generations of suppressor T cells (TS) and their 
secretary soluble suppressor cytokines (SF) with in between 
Mφ transmitting the signals (fi gure 3, cascade I). DV-
infected Mφ transmit the signal to recruit TS1 cells, which 
secrete a suppressor cytokine, SF1. The suppressor signal of 
SF1 is transmitted via live syngeneic Mφ to recruit a second 
subpopulation of suppressor T cells (TS2), which produce 
another soluble, prostaglandin-like suppressor cytokine 
(SF2). SF2 induces production of a third subpopulation 
of suppressor T cells (TS3), which suppresses humoral 
immune response in an antigen-specifi c and genetically 
restricted manner (Shukla and Chaturvedi 1981, 1982, 
1983; Chaturvedi 1984). Of two polypeptide chains of SF1 
(Bhargava et al 1990), a-chain bind to the α-chain of the 
SF receptor sites (SF-R) on present on Mφ (Mukherjee et al 
1993a) while the β-chain of SF binds to H-2A determinants 
on Mφ (Mukherjee et al 1993b; 1994). Internalized SF is 
degraded, binds to H-2K antigen and is transported to a site 
other than SF-R on Mφ membrane for recruitment of TS2 
cells (Tripathi et al 1997). DV-induced suppressor pathway 
suppresses antigen-specifi c antibody production including 
that of enhancing antibody. Thus increased replication 
of the virus mediated by the enhancing antibody and the 
immunopathology mediated by the immune-complex is 
prevented. On the other hand, suppression of neutralizing 
antibody would delay elimination of DV from the body 
causing pathological lesions (Chaturvedi et al 1984, 2007). 
Suppressor T cell activity, regulating B and T cell response 
in dengue type 3 virus-infected mice has been shown 
(Nagarkatti and Nagarkatti 1983). 
5.4.2 DV-specifi c antibody cascade: Cascade 2: As shown 
in fi gure 3 (cascade 2) DV induces generation of helper T 
cells in mouse spleen which enhance the antigen-specifi c 
antibody plaque forming cell count in syngeneic mice 
(Chaturvedi et al 1987). The DV-specifi c helper T cells 
secrete a soluble cytokine, the helper factor (HF) (Chaturvedi 
et al 1992a) which is a disulphide bonded double chain 
structure, one chain having antigen and the other having 
I-A determinants; the presence of both chains is essential 
for helper activity (Chaturvedi et al 1991b). HF binds to the 
surface of macrophage and the helper signal is transmitted 
only by a close physical contact of the plasma membranes 
of the signal presenting cells (helper T cell or HF-adsorbed 
macrophage) and B cells (Chaturvedi et al 1992b; Rizvi et al 
1993). Th and HF helped increased activity of B cells results 
in production of DV-specifi c antibodies that are protective; 
and also production of enhancing antibody that mediate 
antibody dependent enhancement (ADE) of infection 
resulting in DHF (fi gure 3, cascade 2).
5.4.3 Helper T cell cascade, cascade 3: Helper cell type-1 
(Th1) cells secrete interferon-gamma (IFN-γ), interleukin-
2 (IL-2) and tumour necrosis factor-α (TNF-α) and are 
responsible for cell-mediated infl ammatory reactions, 
delayed type hypersensitivity, tissue injury in infections 
and autoimmune diseases. Th2 cells secrete IL-4, IL-5, 
IL-6, IL-10, and IL-13 and are associated with help for B 
cell antibody production. Cross-regulation of Th1 and Th2 
is primarily mediated by IL-10 and IFN-γ respectively. In 
a number of parasitic, fungal, bacterial and viral infections 
such as human immunodefi ciency virus, herpes simplex 
and infl uenza viruses, a Th1 response is linked to recovery 
from infection while a Th2-type response tends to lead to 
severe pathology and exacerbation of the disease (reviewed 
by Mosmann and Sad 1996). A balanced helper T cell-type 
1 (Th1) cytokine response and Th2-type cytokine response 
controls immune response to microbe. During the epidemic 
of DHF at Lucknow during 1996 the pattern of above 
cytokines and their mRNA were studied. For the fi rst time 
it was reported that a shift from predominant Th1 response 
seen in patients with DF to Th2 response (fi gure 3, cascade 
3) in severe dengue disease (Chaturvedi et al 1999a). By 
suppressing protective Th1 responses the regulatory T cells 
may enhance the Th2 response and increase the infection-
induced. Both, the regulatory T cell and Th2 cell secrete 
IL-10 and TGF-β (Agarwal et al 1999b) thus disturbing the 
fi ne balance in the different cytokines causing a “Cytokine 
Tsunami” and severe dengue disease fi gure 3, cascade 3).
5.4.4 Cytotoxic cascade, cascade 4: A unique cytokine, 
cytotoxic factor (CF) which is produced by CD4+ T cells 
during dengue virus infection of mice and man. The amino-
terminal sequence of CF has no homology with any of 
the known proteins. Majority of the patients with dengue 
show the presence of CF in their sera, with peak amounts 
in the most severe cases of DHF grade IV (Chaturvedi et 
al 1999b). CF selectively kills CD4+ T cells and H-2A- 
macrophages (Mφ) and induces H-2A+ Mφ to produce 
another cytokine, the Mφ cytotoxin (CF2) that amplifi es the 
effect of CF (fi gure 3, cascade 4). CF was detected in about 
70% of the stored sera from patient with dengue at Bangkok 
at AFRIMS (Mukerjee et al 1997) and later at Lucknow, 
India during the fi rst extensive epidemic of DHF in India 
in 1996. CF was purifi ed from the pooled sera of the DHF 
patients. On intravenous inoculation into mice it increased 
capillary permeability and damaged the blood-brain barrier, 
indicating its role of CF in the pathogenicity (Mukerjee 
et al 1997). CF and CF2 may be pathogenesis-related 
proteins, capable of reproducing DHF-like pathological 
lesions in mice (fi gure 3, cascade 4), such as increased 
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capillary permeability, cerebral edema, and blood leukocyte 
changes (Chaturvedi et al 1991a; 1997). CF is produced in 
ex vivo cultures of CD4+ T cells obtained from peripheral 
blood of the patients with severe dengue disease (Agarwal 
et al 1998). Human peripheral blood leucocyte cultures 
inoculated with DV produce CF (Chaturvedi et al 1999c). 
The production of CF precedes the clinical illness and is 
present in 100% patients with DF/DHF unto the 4th day of 
illness, then declines and is not detectable after the 20th day 
of illness (Chaturvedi et al 1999b). Since CF is DV-specifi c 
it can be used for developing a diagnostic kit. The DHF-like 
pathological lesions produced by CF/CF2 can be prevented 
by pretreatment of mice with the anti-CF antibodies. Further, 
active immunization of mice using CF as antigen protects 
them against subsequent challenge with CF. Challenge of 
such mice with a lethal intracerebral dose of DV results in 
death without appearance of clinical symptom of the disease 
(Chaturvedi et al 1994). CF/CF2 induce Mφ to produce free 
radicals, nitrite, reactive oxygen and peroxynitrite (Misra et 
al 1996a, b; 1998; Chaturvedi et al 1997, 2000, 2006a). The 
free radicals, besides killing the target cells by apoptosis also 
directly upregulate production of proinfl ammatory cytokines 
IL-1β , TNF-α, IL-8, and hydrogen peroxide in Mφ (fi gure 
4). Oxidative stress develops since early days of onset of 
dengue infection. Plasma protein carbonylation, protein 
carbonylation to protein-bound sulphydryl group ratio are 
reported to predict DHF/DSS (Soundravally et al 2008). The 
change in relative levels of IL-12 and TGF-β shifts a Th1-
dominant response to a Th2-biased response resulting in an 
exacerbation of dengue disease. The vascular permeability is 
increased due combined effect cytokine tsunami, release of 
histamine, free radicals and the products of the complement 
pathway etc. Thus the key player appears to be CF/CF2, but 
their activity is regulated by CF-autoantibodies generated 
(fi gure 4) in patients with dengue disease (Chaturvedi et al 
2001).
5.5 Effect of DV infection on megakaryocytes and 
platelets
One of the classical features of DF/DHF is thrombocyto-
poenia. The occupational and non-occupational exposure 
to toxic hexavalent chromium Cr (VI) is common so is the 
infection with DV in this country. Therefore, the effects of 
DV infection on peripheral blood cells of mice fed Cr (VI) 
with drinking water (for 3 to 9 weeks) were investigated. 
It was observed that in Cr (VI) fed mice the DV-induced 
thrombocytopoenia was abrogated (Shrivastava et al 2005). 
Trivalent chromium picolinate (CrP) is used worldwide as 
micronutrient and nutritional supplement. Another study 
was therefore, carried out to investigate the effects of CrP 
on various haematological parameters during DV infection 
of mice. The fi ndings showed that the adverse effects of 
DV infection, especially on platelets and leucocytes, were 
abrogated by pretreatment of mice with CrP (Shrivastava et 
al 2007). The therapeutic utility of CrP in viral infections 
including dengue needs to be studied in depth. In a study, 
Basu et al (2008) examined the effect of DV-2 on the 
in vitro growth and differentiation of thrombopoietin-
induced megakaryopoiesis of cord blood CD34+ cells. 
Figure 4. Increased vascular permeability mediated by the cytotoxic factor. Please see the text.
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They found that DV-2 inhibits in vitro megakaryopoiesis 
and induce apoptotic cell death in a subpopulation of early 
megakaryocytic progenitors. These events might contribute 
towards the origin of thrombocytopenia in dengue disease. 
In another study they show that DV-2 exposure can 
activate platelets with increase in P-selectin expression 
and fi brinogen-binding property. Atomic force, scanning 
and transmission electron microscopy also showed typical 
activation-related morphological changes such as altered 
platelet membrane architecture, degranulation, and presence 
of fi lopodia and dilatation of the open canalicular system 
in the DV-2-exposed platelets but not in the controls. This 
suggests that DV-2 may directly interact with and activate 
platelets and thus may be responsible for thrombocytopoenia 
(Ghosh et al 2008).
5.6 Infl uence of host genetics on dengue disease
The profound infl uence of the host’s genetic makeup on 
susceptibility/resistance to infections has been established in 
numerous studies. In a review paper the existing knowledge 
dealing with the host genetics and its implication in the 
pathogenesis of the severe dengue disease is presented 
(Chaturvedi et al 2006b). The polymorphic transporter 
associated with antigen processing (TAP) 1 and TAP2 
genes encode subunits of the transporter that delivers 
peptides to the human leukocyte antigen class I molecules. 
Soundravally and Hoti (2007a) have reported that TAP1 gene 
polymorphism is associated with severe dengue infection. In 
another report on TAP 2 gene polymorphism in dengue, they 
have suggested that heterozygous pattern at TAP2 379 locus 
confers susceptibility to DHF, and TAP2 665 THR/ALA 
genotype was found to be a risk factor for development of 
DHF (Soundravally and Hoti 2007b).
5.7 Development of diagnostic kits
Development of a quick, sensitive, specifi c and cheaper 
diagnostic test is an urgent need. 
A number of kits are commercially available for the 
diagnosis of DV infection but they need strict quality 
control. The National Institute of Virology, Pune is 
producing a kit and is supplying all over India. Work is 
going on in some institutions of India to develop a better kit. 
Parida and colleagues have developed ‘dip-stick’ diagnostic 
ELISA kits for the diagnosis of DV infection in the fi eld 
situations (Parida et al 2001; Abhyankar et al 2006). They 
have also developed fusogenic peptide as diagnostic marker 
for detection of fl aviviruses (Pattnaik et al 2006). Anandarao 
et al (2005) developed a customized recombinant dengue 
multiepitope protein (r-DME-G) that can specifi cally detect 
the IgG class of antidengue antibodies in patient sera. Using 
this strategy, they have created another dengue multiepitope 
protein, r-DME-M, with specifi city for the IgM class of 
antidengue antibodies. The purifi ed protein was used to 
develop an IgM ELISA and has been adapted to a rapid strip 
test format (Anandarao et al 2006). Further, r-DME-G and r-
DME-M proteins have been produced in bulk (Tripathi et al 
2007a, b). This approach may circumvent the drawbacks of 
the whole virus antigen-based commercial kits. Hapugoda et 
al (2007) have designed a novel tetravalent chimeric antigen 
fusing envelope domain III of each of the four DV types and 
have demonstrated that this tetravalent antigen can function 
as a diagnostic tool of high sensitivity and specifi city. The 
serodiagnosisis of DV infection is confi rmed by RT-PCR 
and Nested PCR that have been further improved by real 
time RT-PCR and Multiplex-PCR. Parida et al (2005) have 
developed a gene based amplifi cation technique, which 
they call, RT-LAMP. Recently, Saxena et al (2008) have 
developed a single step Multiplex-RT-PCR for the detection 
and typing of dengue viruses.
5.8 Development of dengue virus vaccines
DV was discovered more than sixty years back but we do 
not have an effective vaccine against it, which indicates 
problems in its development. The problems are several, 
e.g. the pathogenesis of DHF is not fully known, and 
absence of an animal model for the dengue disease and 
pre-existing heterotypic dengue antibody is a risk factor 
for DHF. Therefore, a tetravalent vaccine that prevents 
infection with all four DV serotypes is needed. Natural 
DV infection induces long-lasting protective immunity 
only to the same serotype. A tetravalent formulation that 
retains the immunogenicity of all four serotypes has proven 
diffi cult, requiring the use of more complicated, multiple-
dose immunization regimens. A detailed discussion on this 
problem is presented elsewhere (Chaturvedi et al 2005). 
In spite of the problems, the surge in publications on the 
development of dengue vaccines based on new generations 
of biotechnology techniques, indicate the profound interest 
and urgency for combating the dengue disease. The effi cacy 
and safety of some of the new vaccine candidates have been 
evaluated and proven in human preclinical/ clinical trials 
(Chaturvedi et al 2005). Only the Indian initiative in this 
fi eld is presented here. In recent years, the carboxy-terminal 
region of the major dengue virion envelope (E) protein, 
known as domain III (ED III), has emerged as a signifi cant 
sub-unit vaccine candidate. In a novel approach, Jaiswal
et al (2004) have expressed and purifi ed recombinant domain 
EDIII that refolds in vitro and protects cells in culture 
against DV-2 infection by blocking the virus from binding to 
host cells. Khanum et al (2006) have created a recombinant 
adenovirus capable of expressing the EDIII of DV-2 and 
tested it in combination with a plasmid encoding the same 
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domain to determine its potential as a possible dengue 
vaccine candidate. Using two regimens they have shown 
induction of neutralizing antibodies and Th1 type response. 
Further, they have described construction of a recombinant, 
replication-defective Ad (rAd) vector encoding a chimeric 
antigen made of in-frame linked EDIIIs of DV serotypes 2 
and 4. Using this rAd vector, in conjunction with a plasmid 
vector encoding the same chimeric bivalent antigen, in a 
prime-boost strategy, they have shown that it is possible to 
elicit equipotent neutralizing and T cell responses specifi c to 
both DV serotypes 2 and 4 (Khanam et al 2007) This work 
has implications for the development of safe and effective 
tetravalent dengue vaccines.
6. Conclusions and future perspectives 
Dengue virus infection is endemic in India with frequent 
epidemics of DF/DHF. All the four serotypes are circulating 
resulting in concurrent infection with two DV. In the last 
few years the predominant serotype is DV-3. The vector 
has adapted to extremes of warm and cold weather resulting 
in occurrence of dengue cases round the year. Dengue and 
the vector have been reported in the arid zones of Rajasthan 
(Chouhan et al 1990; Angel and Joshi 2008). There are 
large number of reports on atypical clinical presentations 
but they are not backed by virological studies due to 
lack of such facilities at most parts of the country. There 
is no adequate animal model for DHF and a number of 
hypotheses have been put forward to explain the vascular 
leakage. With massive efforts all over the world the vaccine 
is round the corner. The problem of dengue is mammoth in 
this country that is compounded by the huge population, 
poor medical and diagnostic facilities, inadequate mosquito 
control and all the ground conditions that favour expansion 
of the vector. This country needs a large number of virus 
laboratories that may provide quick and reliable diagnosis. 
Efforts will have to be made to develop improved, proactive, 
laboratory-based surveillance systems that can forecast 
impending dengue epidemics. This will alert the public to 
take action and physicians to diagnose and properly treat 
DF/DHF cases. There is need to have a strong epidemiology/ 
pathology/experimental pathology backup. Are our efforts 
adequate? Our efforts are limited only to the stage of 
crisis management. We need dedicated teams to solve the 
problems and minimize the human suffering.
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